Skip to main content
    PeptideAuthority
    JH

    Dr James Harrington, MBChB, MRCP

    Clinical Endocrinology — NHS England (consultant endocrinologist)

    Profile last reviewed: 2026-05-20

    Dr Harrington is a consultant endocrinologist with clinical experience in GLP-1 agonist prescribing and growth hormone disorders. He reviews our clinical content, ensuring accuracy in dosing information, side effect profiles, and UK regulatory context.

    Credentials

    • MBChB — University of Manchester
    • Member of the Royal College of Physicians (MRCP)
    • Consultant in Clinical Endocrinology, NHS England
    • Clinical experience with GLP-1 receptor agonist prescribing and GH-axis disorders

    Professional registrations

    • General Medical Council (GMC): Registered with a licence to practise
    • Royal College of Physicians: Member (MRCP)

    GMC registration number is verifiable on the GMC Medical Register by name. We do not republish registration numbers here to align with standard editorial practice on personal-data minimisation.

    Role on the editorial board

    Lead reviewer for clinical content — GLP-1 medicines, endocrine and metabolic conditions, prescribing context, and NHS pathway accuracy. Reviews the GLP-1 Centre and the metabolic-and-weight hub content.

    Conflict of interest disclosures

    • No equity in pharmaceutical companies, peptide manufacturers, or weight-management clinics.
    • Has accepted CME-accredited educational sponsorship for endocrinology conferences from licensed pharmaceutical companies (declared annually per GMC standards).
    • Does not accept consulting or advisory fees from online prescribing services or peptide retailers.
    • Does not personally prescribe or supply any of the unlicensed peptides reviewed on this site.

    Disclosures are reviewed annually and updated at the date shown above. See the conflict-of-interest policy for the wider framework.

    Sections reviewed

    • GLP-1 Centre — all brand and active-ingredient pages
    • Metabolic and Weight hub and spokes
    • Mounjaro / Wegovy / Ozempic side-effect pages
    • GLP-1 pancreatitis, gallbladder, pregnancy & fertility explainers

    Citation policy

    Clinical claims must trace to NICE technology appraisals, MHRA Drug Safety Updates, the relevant Summary of Product Characteristics (SmPC), or peer-reviewed clinical trial publications. Off-label use is flagged as such with the appropriate UK regulatory framing.

    The site-wide methodology is documented in our evidence grading methodology and editorial standards.

    About the editorial board

    Peptide Authority’s editorial board is responsible for the accuracy, evidence-grading, and UK regulatory framing of the content on this site. Read more about how we work in editorial standards and the corrections policy.

    Other reviewers